Authors
Latest:
Aligning Tactics with the Goals of Value-Based CareThe marketing challenge for pharmaceutical companies has now shifted to "How can we successfully and cost-effectively assist providers in orchestrating better care?" William Febbo reports.
Latest:
Building Healthcare's "Ground Truth" with AIFor pharma leaders, AI can bring about a new reality of seeing a multitude of possible paths, forecasting the interplay of multi-dimensional trends, and charting patient journeys that are based on reality, writes Aswin Chandrakantan.
Latest:
Small Biotechs Gain As the Span of Clinical Trial Outsourcing GrowsSmall biotech companies benefit more from partnering with CROs rather than hiring a chief medical officer.
Latest:
Learning, Retaining, Applying Information: Preparing Reps for Success in the FieldThee most effective way to train sales reps and boost their success is to consider the learner/user experience in all facets, in every training encounter, and on each training platform, writes Shaun McMahon.
Latest:
Is Pharma Losing the Centerpiece of Its Market Access Toolbox?With employers and the public scrutinizing drug prices like never before, rebates-long at the center of pharma’s market access strategy-may be losing their luster, writes Amber Gilbert.
Latest:
How DSCSA Changes the Licensing LandscapeA look at the Drug SUpply Chain Security Act and how it impacts serialization and third-party logistics licensing.
Latest:
Closing Pharma’s Digital DivideOvercoming the challenges of digital brand management will involve choices in spending and channels.
Latest:
Managing Local Language Regulatory SubmissionsThe call to reduce market entry times for life-saving new drug therapies is becoming more urgent. What constitutes best practice in managing translations in today’s regulatory affairs environment? Nancy Pollini reports.
Latest:
What the Age of Multi-Localism Means for PharmaNew realities are transforming the global environment and upending a business model based on the presumption of ever more connected markets. Paul A. Laudicina asks, What does this new age mean for pharma?
Latest:
Driving Access to the Most Efficient Form of HealthcareA look at the pharmaceutical value chain and how pricing concerns and patient centricity fits in to improving access.
Latest:
Curing Big Pharma’s Litigation Spend Woes with Data-Driven MedicineDaniel Gold looks at the benefits of centralising an organization's data in a core repository and adopting a comprehensive business intelligence strategy.
Latest:
Creating Defensible Data Analytics Moats for a Competitive AdvantageKarim Damji discusses how Artificial Intelligence (AI)-informed Systems of Intelligence and Virtual Assistants offer powerful solutions to the common struggles pharma companies face today.
Latest:
Social Science Behavior Change Models: The Key to More Targeted MessagesBehavioral social scientists try to understand human behavior and find ways to make people accept and adapt it. Pharma sales and marketing is no different – especially with the launch of a new product, writes Charles Daramola.
Latest:
Navigating Unplanned Value Inflection Points in International AlliancesDealing with significant unplanned events in alliances is important work. It's is critical to maintain the ongoing health of the alliance by applying sound governance principles and minimizing the disruption to normal operations wherever possible. So how can you stabilize your ships in rough seas?
Latest:
The Genetic Data Gold Rush: Balancing Privacy and Health OutcomesAs pharm execs look to real-world data to aid in translational research and close the gap from traditional clinical trials to real-world efficacy, there are three foundational pillars to build from. Bill Fox reports.
Latest:
The Future of JAK InhibitorsPharma companies have faced hurdles in gaining approval of Janus kinase (JAK) inhibitors for the treatment of rheumatoid arthritis. Denise Baldock, Elizabeth Baynton, Amanda Baskett, and Nicola Bailey look at what can be learned from the lessons of the past.
Latest:
Advocacy and Access in a Complex MarketplaceNick Hicks and Bruno Santoni explore the complex plasma-derived medical products marketplace.
Latest:
Patent Protection for Cannabis?Amid a still-difficult environment for enforcing cannabis-related patents, this article explores some of the types of patent protection available for cannabis-based therapies and inventions.
Latest:
Patent Protection for Cannabis?Amid a still-difficult environment for enforcing cannabis-related patents, this article explores some of the types of patent protection available for cannabis-based therapies and inventions.
Latest:
In Blockchain We TrustThe next generation of supply chain shows an increasing need for blockchain technology.
Latest:
Is the Price Right? An Overview of US Pricing StrategiesBruno Delagneau reviews the current landscape for price-setting in the US and suggests that it’s time for pharma to change their practices.
Latest:
Bribery and Corruption Compliance in UK Pharma: Where Are We Now?When it first came into force the UK Bribery Act 2010 was deemed to be revolutionary. Looking back, what has been its impact on pharma? Chris Cartmell and Jo Pisano report.
Latest:
FDA's $100 Million RWE Project: Making It All It Can BeFDA's proposal to build a modern system to gather real-world evidence (RWE) from about 10 million individuals could have profound implications, but it will realize its potential only if FDA takes a more expansive view of what RWE can be, writes Paul Glimcher.
Latest:
RMAT Designations: Lessons Learned on the “Clinical Evidence” RequirementThe Regenerative Medicine Advanced Therapies (RMAT) designation was introduced by the 21st Century Cures Act as a pathway to accelerate FDA approval and market entry of regenerative medical therapies. Two years on, William Rose and Suchira Ghosh identify the trends in how FDA assesses the clinical evidence supporting successful RMAT candidates.
Latest:
Pharmacovigilance Software's “Salesforce” MomentAlthough it is unlikely that mock demonstrators will be seen at any drug information or regulatory conferences, pharmacovigilance software is indeed having its “Salesforce” moment.
